Alkermes begins Phase II trial of ALKS 2680 for narcolepsy type 1

Alkermes has commenced the Vibrance-1 Phase II clinical trial to evaluate ALKS 2680 in patients with narcolepsy type 1 (NT1). ALKS …

CalciMedica enrols last patient for Phase IIb acute pancreatitis trial

CalciMedica has announced the completion of patient enrollment for its Phase IIb CARPO clinical trial, which is evaluating the efficacy …

Gain touts positive Phase I results for Parkinson’s therapy

Gain Therapeutics’ GT-02287 was found to be safe and tolerable in the Phase I trial of the therapy in healthy …

EXO Biologics hopes to gain conditional marketing from Phase I/II BPD trial

EXO Biologics is hoping to receive conditional market approval from the European Medicines Agency (EMA) for its bronchopulmonary dysplasia (BPD) …

Lykos concludes European Phase II study for PTSD

Lykos Therapeutics has completed a European Phase II study (MP18) evaluating midomafetamine (MDMA) capsules for post-traumatic stress disorder (PTSD). MP18 is …